Royce & Associates LP Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL

Royce & Associates LP lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 18.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 251,153 shares of the specialty pharmaceutical company’s stock after selling 54,987 shares during the period. Royce & Associates LP’s holdings in Collegium Pharmaceutical were worth $11,628,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Rubric Capital Management LP raised its stake in shares of Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after acquiring an additional 157,743 shares during the period. Vanguard Group Inc. raised its stake in shares of Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after acquiring an additional 29,876 shares during the period. Principal Financial Group Inc. raised its stake in shares of Collegium Pharmaceutical by 0.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after acquiring an additional 3,891 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after acquiring an additional 518,721 shares during the period. Finally, Millennium Management LLC grew its holdings in Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after purchasing an additional 461,914 shares in the last quarter.

Analyst Ratings Changes

A number of research firms recently weighed in on COLL. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Truist Financial set a $58.00 price objective on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Needham & Company LLC reissued a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Finally, Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Insider Activity

In related news, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the sale, the executive vice president directly owned 71,770 shares in the company, valued at $2,900,225.70. This trade represents a 41.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Dieter sold 13,976 shares of Collegium Pharmaceutical stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the sale, the executive vice president owned 77,071 shares in the company, valued at approximately $2,691,319.32. This represents a 15.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.85% of the company’s stock.

Collegium Pharmaceutical Trading Down 0.3%

NASDAQ COLL opened at $33.68 on Thursday. Collegium Pharmaceutical, Inc. has a one year low of $28.74 and a one year high of $50.79. The company has a 50-day simple moving average of $34.19 and a 200-day simple moving average of $41.50. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The firm has a market capitalization of $1.09 billion, a PE ratio of 16.51 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. During the same period in the previous year, the business posted $1.49 EPS. The company’s quarterly revenue was up 8.9% on a year-over-year basis. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.